scholarly journals Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study

2009 ◽  
Vol 101 (4) ◽  
pp. 575-581 ◽  
Author(s):  
T Wethal ◽  
M-B Lund ◽  
T Edvardsen ◽  
S D Fosså ◽  
A H Pripp ◽  
...  
2017 ◽  
Vol 17 (2) ◽  
pp. 299-305 ◽  
Author(s):  
Filipe Dinato de Lima ◽  
Martim Bottaro ◽  
Ritielli de Oliveira Valeriano ◽  
Lorena Cruz ◽  
Claudio L. Battaglini ◽  
...  

The purpose of this study was to compare fatigue, strength, body composition, muscle thickness, and muscle quality between Hodgkin’s lymphoma survivors (HLS) and apparently healthy subjects matched by age, gender, and physical activity levels (CON). Twelve HLS (32.16 ± 8.06) and 36 CON (32.42 ± 7.64) were enrolled in the study. Fatigue was assessed using the 20-item Multidimensional Fatigue Inventory, muscle strength using an isokinetic dynamometer, body composition using dual-energy X-ray absorptiometry, and thickness and muscle quality using B-mode ultrasound. Differences between HLS and CON were analyzed using independent samples t tests. No significant differences were observed between groups for any demographic characteristics: age ( P = .922), weight ( P = .943), height ( P = .511), body mass index ( P = .796), fat mass ( P = .688), fat-free mass ( P = .520), and percent body fat ( P = .446). No significant differences were observed for strength (peak torque; P = .552), relative peak torque ( P = .200), muscle thickness ( P > .05) and muscle quality ( P > .05). However, self-perceived fatigue was significantly higher in HLS than in CON ( P = .009). It appears that when HLS are matched by age and physical activity levels to CON, no significant difference in body composition, muscle thickness, muscle quality, or strength is observed. Self-perceived fatigue, as predicted, is higher in HLS, which may have implications and should be considered when prescribing exercise training to this cancer population.


2007 ◽  
Vol 96 (9) ◽  
pp. 1442-1449 ◽  
Author(s):  
C E Kiserud ◽  
A Fosså ◽  
H Holte ◽  
S D Fosså

2019 ◽  
Vol 4 (4) ◽  
pp. 699-705 ◽  
Author(s):  
Adam L. Holtzman ◽  
John M. Stahl ◽  
Simeng Zhu ◽  
Christopher G. Morris ◽  
Bradford S. Hoppe ◽  
...  

2020 ◽  
Vol 36 (4) ◽  
pp. 536-542
Author(s):  
Devon Noonan ◽  
Matthew LeBlanc ◽  
Cherie Conley ◽  
Habtamu Benecha ◽  
Ashley Leak‐Bryant ◽  
...  

2004 ◽  
Vol 22 (10) ◽  
pp. 1864-1871 ◽  
Author(s):  
O. Hequet ◽  
Q.H. Le ◽  
I. Moullet ◽  
E. Pauli ◽  
G. Salles ◽  
...  

Purpose To assess the cardiac status of the long-term survivors and to estimate the incidence and the features of subclinical cardiotoxicity induced after conventional treatment with doxorubicin for non-Hodgkin's lymphoma or Hodgkin's lymphoma. Patients and Methods We analyzed a group of patients who previously received doxorubicin-based chemotherapy for lymphoma. Echocardiograms were performed at least 5 years after therapy with anthracyclines. Clinical cardiomyopathy was defined by the presence of clinical signs of congestive heart failure (CHF). Subclinical cardiomyopathy was defined by decrease of left ventricular fractional shortening (FS) without clinical signs of CHF. Cumulative dose of doxorubicin, male sex, older age, relapse, radiotherapy (mediastinal or total-body irradiation), autologous stem-cell transplantation, high-dose cyclophosphamide, and cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia, familial history of cardiac disease, being overweight, and smoking history) were evaluated as potential risk factors for the development of cardiac dysfunction. Results Of 141 assessable patients (median age, 54 years; median cumulative dose of doxorubicin, 300 mg/m2), only one developed CHF. Criteria of subclinical cardiomyopathy were found in 39 patients. In multivariate analysis, factors that contributed to decreased FS were male sex (P < .01), older age (P < .01), higher cumulative dose of doxorubicin or association with another anthracycline (P = .04), radiotherapy (P = .04), and being overweight (P = .04). Conclusion Cardiac abnormalities can occur in patients treated with doxorubicin for lymphoma in the absence of CHF, even in patients who received moderate anthracycline doses. Male sex, older age, higher dose of doxorubicin, radiotherapy, and being overweight were risk factors for the development of cardiomyopathy.


Lung ◽  
2012 ◽  
Vol 191 (1) ◽  
pp. 117-134 ◽  
Author(s):  
Ezzeldin M. Ibrahim ◽  
Ghieth A. Kazkaz ◽  
Khaled M. Abouelkhair ◽  
Mubarak M. Al-Mansour ◽  
Turki M. Al-Fayea ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document